Latest Clinical News

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer (10-23-2014)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According to estimates from the American Cancer Society,... Continue Reading

FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC (10-22-2014)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to an investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (10-21-2014)

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results of this study were recently reported in The Lancet... Continue Reading

Second-line Avastin Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer (10-20-2014)

Adding Avastin® (bevacizumab) to chemotherapy in second-line treatment of advanced HER2-negative breast cancer improves progression-free survival. Results of the phase III TANIA trial evaluating the role of Avastin® in advanced breast cancer were recently... Continue Reading

Study Suggest That Psoriasis Patients Have Increased Cancer Risk (10-15-2014)

Based on recently analyzed data from a retrospective analysis of commercial insurance claims, rates of cancer are higher in patients with psoriasis and that some anti-psoriatic drugs may pose a higher risk than others. Dr. Alexa B. Kimball of Massachusetts... Continue Reading

Ask the Expert: Making Informed Decisions about Early-Stage Breast Cancer Treatment (10-15-2014)

October 23, 2014 at 6:00pm EDT CancerConnect live Web Chat with an Expert sereis presents: “Rethink Pink: From Awareness to Knowledge, Advice for women newly diagnosed with early stage breast cancer.” On October 23, 2014 at 6:00pm EDT you will have... Continue Reading

Anamorelin May Be First Drug to Treat Cancer Cachexia (10-14-2014)

A new drug, anamorelin, may be the first ever to effectively improve cancer cachexia. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] Cancer cachexia is a “wasting”... Continue Reading

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma (10-13-2014)

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain,... Continue Reading

Radiation Therapy Benefits Selected Patients With Node-Positive Prostate Cancer (10-13-2014)

According to a recent report published in The Journal of Clinical Oncology, men with advanced prostate cancer involving the lymph nodes may benefit from treatment with radiation in addition to hormonal therapy. Prostate cancer is the most commonly diagnosed... Continue Reading

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia (10-10-2014)

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell... Continue Reading

Impressive Survival Gains with New First-Line Therapy for HER2-Positive Metastatic Breast Cancer (10-9-2014)

According to recent findings, the combination of targeted agents Herceptin® (trastuzumab) and Perjeta® (perjeta) significantly improves survival for patients with HER2-positive metastatic breast cancer when added to chemotherapy. This data was presented... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (10-8-2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer... Continue Reading

Next Page »